Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dianeal Low-Calcium with 4.25% Dextrose is a sterile, nonpyrogenic peritoneal dialysis solution manufactured by Baxter Healthcare (now under Vantive US Healthcare). It is indicated for the management of acute or chronic renal failure in patients requiring peritoneal dialysis. The solution contains 4.25% dextrose hydrous, which serves as the primary osmotic agent to facilitate ultrafiltration and the removal of metabolic waste products and excess fluid across the peritoneal membrane. The 'Low-Calcium' designation refers to a calcium chloride concentration of 2.5 mEq/L, which is intended to help manage calcium balance in dialysis patients. The formulation also includes electrolytes such as sodium chloride, sodium lactate, and magnesium chloride to maintain physiological balance during the dialysis process.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dianeal Low-Calcium with 4.25% Dextrose.